Evidence map›Paper›PMID 41663864›Full record

ReviewPituitary2026

Gamma knife radiosurgery vs fractionated radiotherapy : gender difference in efficacy and toxicity.

Cecilia Piazzola, Thomas Graillon, Nicolas Sahakian, Henry Dufour, Jean Regis, Thierry Brue, Frederic Castinetti

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Cecilia PiazzolaINSERM U1251, Marseille Medical genetics, Department of endocrinology, Aix Marseille University, Assistance Publique-Hopitaux de Marseille, Marseille, France.
Thomas GraillonINSERM U1251, Marseille Medical genetics, Department of endocrinology, Aix Marseille University, Assistance Publique-Hopitaux de Marseille, Marseille, France.
Nicolas SahakianINSERM U1251, Marseille Medical genetics, Department of endocrinology, Aix Marseille University, Assistance Publique-Hopitaux de Marseille, Marseille, France.
Henry DufourINSERM U1251, Marseille Medical genetics, Department of endocrinology, Aix Marseille University, Assistance Publique-Hopitaux de Marseille, Marseille, France.
Jean RegisINSERM, INS, Institut Neurosciences Systèmes, Department of Functional Neurosurgery & Radiosurgery, Aix Marseille University, Marseille, France.
Thierry BrueINSERM U1251, Marseille Medical genetics, Department of endocrinology, Aix Marseille University, Assistance Publique-Hopitaux de Marseille, Marseille, France.
Frederic CastinettiINSERM U1251, Marseille Medical genetics, Department of endocrinology, Aix Marseille University, Assistance Publique-Hopitaux de Marseille, Marseille, France. frederic.castinetti@ap-hm.fr.ORCID http://orcid.org/0000-0002-1808-8800

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although radiation therapy is used less frequently in the treatment of functioning and nonfunctioning pituitary adenomas, it still plays a role to control volume and secretion. Radiation therapy remains to be considered in the therapeutic algorithm for these diseases, as mentioned in all recent national and international guidelines. Recent studies have focused on the use of stereotactic approaches, either given as a single dose or as a fractionated one. However, some patients may still benefit from conformal fractionated radiotherapy. The choice among these procedures is currently based mainly on adenoma's profile in terms of size, quality of the radiological definition, invasiveness, and aggressiveness, as well as local availability. Endocrine efficacy in functioning pituitary adenomas and tumor control in nonfunctioning pituitary adenomas seem equivalent regardless of the technique. This review will try to determine whether gender should also be considered as a predictive factor of efficacy and toxicity.

Indexed as

Pituitary NeoplasmsRadiosurgeryAdenomaDose Fractionation, RadiationFemaleHumansMaleTreatment OutcomeAcromegalyCushing’s diseaseFractionated radiotherapyGamma knifeHypopituitarismStereotaxy

Identifiers

PMID41663864

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.